Floatz Rating
B59/100
Confidence
Indicative
Sponsor
BeOne Medicines
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06585488CT.gov A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | — | Terminated | — | — | — |
NCT06427941CT.gov A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05789069CT.gov A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05768932CT.gov BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05238883CT.gov A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04777162CT.gov Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer | — | Unknown | — | — | — |
NCT04276493CT.gov Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | — | Completed | — | — | — |
NCT02500199CT.gov Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pyrotinib (this asset) | BeOne Medicines | P2 | B · 59 |
| Rivoceranib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P4 | BBB |
| Fluorouracilum | I-Mab Biopharma US Limited | P4 | BB |
| Oxaliplatin | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Epirubicin | Rondo Therapeutics | P3 | BB |
| Pembrolizumab | Eikon Therapeutics | P3 | BB |
| Docetaxel | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
+42 more in the Gastric Cancer cohort
Other indications for Pyrotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 70 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 66 |
| Invasive Breast Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pyrotinib in Gastric Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pyrotinib-gastric-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →